Drug Trial Radar · NCT05645627
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Feb 10, 2023
Primary completion
Aug 9, 2023
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
Conditions
- Psoriasis
Interventions
IBI112Drug
IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
placebo /IBI112Drug
placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
IBI112Drug
IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients achieving Psoriasis Area and severity index(PASI) 90 at week 16Time frame: Week 16
- Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.